Moderna Inc. (NASDAQ:MRNA) stock soared Wednesday after the company and Merck reported positive Phase 3 results for a personalized mRNA cancer vaccine, marking a major milestone for the emerging technology. Shares jumped more than 100%, reaching levels not seen since May 2024.
Among the Moderna shareholders benefiting from the surge is President Donald Trump.